Finland· FI-REL-REL55966
Sunitinib Avansor
A sunitinib product containing sunitinib malate, registered in Finland by Avansor Pharma Oy. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Sunitinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX01 (sunitinib), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Sunitinib · ATC L01EX01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of sunitinib costs, country by country.
Normalised to the WHO defined daily dose (33 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sunitinib · price per daily dose (33 mg)
USD · FX 28 Sept 2026
- CH Switzerland$100.88
The record
At a glance
Fimea (Finland)- Active substance
- Sunitinib malate
- Manufacturer
- Avansor Pharma Oy
- Country
- Finland (FI)
- ATC code
- L01EX01
- ATC class
- Sunitinib
- Defined daily dose
- 33 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
464 interactions on record for sunitinib.
Graded by severity as the source publishes them — 99 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sunitinib · interactions on record
464 records
- 99 severe
- 362 moderate
- 3 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sunitinib in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesSunitinib malateNorthStar RxLLC
- CzechiaSUNITINIB SANEXCELJ.J. BISHOP HEALTH a.s., Praha
- BelgiumSunitinib Krka 50 mgKRKA d.d. Novo mesto
- SwedenSunitinib Avansor 50 mg Kapsel, hårdAvansor Pharma Oy
- IrelandSutent 50 mg hard capsulesPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Luxembourg · Sunitinib Synthon
- Malta · Subinit
- Netherlands · Sunitinib Malate Eugia, Sunitinib Synthon
- Poland · Sunitinib, Sunitinib Synthon
- Sweden · Sunitinib Avansor
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0edc01d2-8841-45b1-ba82-8e3400397dde GET /v1/drugs/0edc01d2-8841-45b1-ba82-8e3400397dde?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "33",
"form": "kapseli, kova",
"route": "Suun kautta",
"ddd_unit": "mg",
"strength": "50 mg",
"atc_label": "sunitinibi",
"ma_number": "37760",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL55966",
"authorised_at": "2021-08-27"
}See everything about sunitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.